Showa Pharmaceutical University · Division of Practical Pharmacy

Research keywordsoncology pharmacy・antiemetic therapy・pancreatic cancer cells・ATR inhibition・Chk1 inhibition・Bcl-xL inhibition・cisplatin symptom care・clinical pharmacy education

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Original paper Sustained Antiemetic Efficacy of Fosnetupitant versus Aprepitant in Carboplatin-based Chemotherapy: A Retrospective Observational Study Hiroshi Inano, Yoshihito Morimoto, Atsushi Kawamura, Taichi Ikegami, Tomoki Niizuma, Kanata Kitagawa, Rie Usami, Kozue Nakagomi, Yuri Anzo, Misaki Uc2026
• Original paper Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: Analysis based on real-world data. Hiroshi Inano, Yoshihito Morimoto*, Kanata Kitagawa, Akito Shibuya, Kozue Nakagomi, Tomohiro Ota, Yuri Anzo, Rika Miyauchi, Aiko Shono, Kazuhiro Watanabe, Katsuya2025
• Note Effect of perioperative docetaxel-induced limb edema on health-related quality of life in patients with early-stage breast cancer: a prospective observational study. Kaori Matsumoto, Yoshihito Morimoto*, Junichiro Wakatsuki, Daiki Sakuma, Keiko Mukouyama, Masayuki Inoue, Ayako Kimura, Iori Hiro2024
• Original paper Comparing the Efficacy of Fosnetupitant, an NK1 Receptor Antagonist in CDDP-Based Regimens, With that of Fosaprepitant and Aprepitant: A Retrospective Observational Study. Hiroshi Inano, Yoshihito Morimoto, Kanata Kitagawa, Akito Shibuya, Kozue Nakagomi, Tomohiro Ota, Yuri Anzo, Rika2024

• 文部科学省 ウィズコロナ時代の新たな医療に対応できる医療人材養成事業 2022年2022
• 日本学術振興会 科学研究費助成事業 若手研究 2025年4月 - 2028年3月 （PARPを標的とした膵臓がんに対する新規併用療法の基礎的研究）
• PARPを標的とした膵臓がんに対する新規併用療法の基礎的研究
• 膵臓がんにおけるDNA損傷修復機構を標的とした新規治療戦略の創出

• Official profile